Clinical trial
G-PLUS (GALLANT, GALLEX and ARMOR - Post Treatment Follow-up Study)
NCT00255645 · AstraZeneca, Industry · Terminated
Key facts
| NCT number | NCT00255645 |
|---|---|
| Title | G-PLUS (GALLANT, GALLEX and ARMOR - Post Treatment Follow-up Study) |
| Official title | A Long-Term, Post-Treatment, Safety Follow-Up, Multi-Center Study in Patients With Type 2 Diabetes Mellitus From the GALLANT, GALLEX or ARMOR Studies. |
| Lead sponsor | AstraZeneca, Industry |
| Status | Terminated |
| Study type | Observational |
| Conditions | Type 2 Diabetes |
| Enrollment | 4,500 |
| Start date | Sep 1, 2005 |
| Completion | Dec 1, 2006 |
| First posted | Nov 21, 2005 |
| Last update posted | Mar 17, 2008 |
| Countries | Argentina, Australia, Belgium, Brazil, Canada, Czechia, Estonia, Finland, France, Germany, Greece, Hong Kong and 28 more |
At a glance
- 100–999 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: